Halozyme Therapeutics Inc (HALO)

[rod5247]

I think we exceed that in 2017.

Do a google of Herceptin Hong Kong and read some of the articles.

Herceptin is approved in China and Roche has an established insurance plan but no announcement about Herceptin SC in China. Herceptin in China major contributor to large increase in international sales. Hong Kong opens the door to mainland China until Herceptin SC gains approval for launch and even afterwards according to articles.

Will the Mexico launch open the door to US? Add Argentina to Chile in South America?

As of Q4, 2015, Herceptin SC annual run rate in EU was over $800 million. Add at least 23 countries to date for international sales assuming launch has occurred in all 28 EU countries. I think it is easy to assume a global annual run rate in excess of $2 billion occurring in 2017. edit: add MabThera SC and HyQ and what do you think?

Roche is anticipating biosimilar competition in second half 2017 for Herceptin/MabThera. I believe SC will be well positioned by then.

Also think Roche looking at potential for Perjeta SC in combination with Herceptin SC is part of long term plan against biosimilars along with other benefits. I am extremely interested in the results of that study and design of next study if there is one.